Company Description
Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies.
The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012.
Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2011 |
| IPO Date | Jun 30, 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Conley Chee |
Contact Details
Address: 35 Cambridge Park Drive Cambridge, Massachusetts 02140 United States | |
| Phone | 617-744-1340 |
| Website | syros.com |
Stock Details
| Ticker Symbol | SYRS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001556263 |
| CUSIP Number | 87184Q107 |
| ISIN Number | US87184Q2066 |
| Employer ID | 45-3772460 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Conley Chee | Chief Executive Officer, President and Director |
| Dr. Richard A. Young Ph.D. | Scientific Founder, Member of Scientific Advisory Board and Director |
| Dr. David A. Roth M.D. | Chief Medical Officer |
| Dr. James E. Bradner M.D. | Founder |
| Dr. Nathanael S. Gray Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Jason Haas | Chief Financial Officer |
| Karen Hunady M.S. | Director of Corporate Communications and Investor Relations |
| Gerald E. Quirk Esq., J.D. | Chief Legal Officer and Head of Business Development |
| Lisa Roberts | Vice President of Human Resources |
| Kristin Stephens | Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 28, 2024 | 144 | Filing |
| Jun 6, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| Apr 23, 2024 | ARS | Filing |
| Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 12, 2024 | PRE 14A | Other preliminary proxy statements |
| Apr 3, 2024 | 144 | Filing |
| Apr 2, 2024 | 144 | Filing |
| Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |